Antiresorptive agents-related osteonecrosis of the jaw (ARONJ) in rheumatoid arthritis

J Bone Miner Metab. 2020 Sep;38(5):739-741. doi: 10.1007/s00774-020-01112-2.

Authors

Yuichiro Fujieda¹, Tatsuya Atsumi²

Affiliations

¹ Department of Rheumatology, Nephrology and Endocrinology, Faculty of Medicine, Hokkaido University, Kita 14, Nishi 5, Kita-ku, Sapporo, 060-8648, Japan. edaichi@med.hokudai.ac.jp.
² Department of Rheumatology, Nephrology and Endocrinology, Faculty of Medicine, Hokkaido University, Kita 14, Nishi 5, Kita-ku, Sapporo, 060-8648, Japan.

PMID: 32591907
DOI: 10.1007/s00774-020-01112-2

No abstract available

Publication types

Letter
Comment

MeSH terms

Arthritis, Rheumatoid* / drug therapy
Autoimmune Diseases*
Bisphosphonate-Associated Osteonecrosis of the Jaw*
Bone Density Conservation Agents* / adverse effects
Humans
Incidence
Osteonecrosis* / chemically induced
Tooth Extraction

Substances

Bone Density Conservation Agents